Elsevier

Clinical Therapeutics

Volume 27, Issue 10, October 2005, Pages 1548-1561
Clinical Therapeutics

Original research
Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: A 24-week, multicenter, randomized, double-blind, parallel-group study

https://doi.org/10.1016/j.clinthera.2005.10.012Get rights and content

Abstract

Background:

Management of type 2 diabetes mellituBackground:026 (DM) that involves uptitration of monotherapy to the maximum dose has been associated with delays in achieving glycemic control and an increased number of adverse events (AEs). Studies have reported the benefits of adding a thiazolidinedione to metformin (MET), but none has compared the effect of adding a thiazolidinedione to MET versus increasing the daily dose of MET to 3 g.

Objective:

The goal of this study was to investigate1026 the benefits of fixed-dose combination rosiglitazone and MET (RSG/MET) compared with high-dose MET monotherapy in patients with type 2 DM.

Methods:

This was a 24-week, multicenter, randomized, 1026 double-blind, parallel-group study. Patients previously treated with MET entered a 4-week, singleblind, run-in period with MET 2 g/d and were then randomized to RSG/MET 4 mg/2 g per day or MET 2.5 g/d. At week 8, medication was escalated to RSG/MET 8 mg/2 g per day or MET 3 g/d. The primary efficacy end point was change in glycosylated hemoglobin (HbA1c) at week 24. Tolerability was assessed, including the frequency and severity of AEs.

Results:

A total of 568 patients comprised the safety 1026 population (MET, 280; RSG/MET, 288) and 551 formed the intent-to-treat group (MET, 272; RSG/MET, 279). Baseline characteristics of the safety population were comparable in the 2 groups; body mass index (mean [SD]) was 32.2 (4.8) kg/m2 and 32.1 (4.9) kg/m2 in the RSG/MET and MET groups, respectively. RSG/MET reduced HbA1c (mean [SD]) from 7.4% (1.0%) to 7.1% (1.1%) at week 24, compared with a reduction from 7.5% (1.0%) to 7.4% (1.1%) with MET (treatment difference, −0.22%; P = 0.001). Fasting plasma glucose (mean [SD]) was reduced from 166.2 (29) to 144.1 (33) mg/dL with RSG/MET and from 169.3 (33) to 164.0 (37) mg/dL with MET (treatment difference, −18.3 mg/dL; P < 0.001). In addition, 54% of patients treated with RSG/MET achieved HbA1c levels <7.0%, compared with 36% with MET (odds ratio, 2.42; P < 0.001). RSG/MET increased homeostasis model assessment (HOMA) estimates of insulin sensitivity by 34.4% versus 6.5% with MET (treatment difference, 24.8%; P < 0.001). HOMA β-cell function increased by 15.9% with RSG/MET versus 2.5% with MET (treatment difference, 14.0%; P < 0.001). RSG/MET decreased C-reactive protein by a mean of 39.4% versus 16.0% with MET (treatment difference, −33.8%; P < 0.001). RSG/MET was generally well tolerated, with the majority of AEs mild to moderate in nature. Serious AEs were reported in 3% of patients receiving RSG/MET and 2% with MET. Overall rates of gastrointestinal AEs were 23% with RSG/MET and 26% with MET; however, there was an increased incidence of diarrhea (14% vs 6%) and abdominal pain (9% vs 6%) with MET. There was a mean (SE) increase in weight with RSG/MET (1.3 [0.22] kg) and a mean decrease (−0.9 [0.26] kg) with MET. Patients receiving RSG/MET reported improvements in treatment satisfaction compared with MET.

Conclusions:

In this study, the RSG/MET fixed-dose1026 combination (8 mg/2 g per day) was an effective and well-tolerated treatment for type 2 DM and enabled more patients to reach glycemic targets than high-dose MET (3 g/d)

References (54)

  • Type 2 Diabetes: Practical Targets and Treatments

    (2002)
  • SaydahS.H. et al.

    Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes

    JAMA

    (2004)
  • LieblA. et al.

    Evaluation of risk factors for develop ment of complications in type II diabetes in Europe

    Diabetologia

    (2002)
  • Effect of intensive blood-glucose control with met formin on complications in overweight patients with type 2 diabetes (UKPDS 34)

    Lancet

    (1998)
  • UK Prospective Diabetes Study 16. Overview of 6 years' ther apy of type II diabetes: A progressive disease

    Diabetes

    (1995)
  • CampbellI.W.

    Need for intensive, early glycaemic control in patients with type 2 diabetes

    Br j Cardiol

    (2000)
  • BrownJ.B. et al.

    The burden of treatment failure in type 2 diabetes

    Diabetes Care

    (2004)
  • BaileyC.J. et al.

    Drug therapy: Metformin

    N Engl J Med

    (1996)
  • DeFronzoR.A. et al.

    Efficacy of metformin in pa tients with non-insulin-dependentdiabetes mellitus

    N Engl J Med

    (1995)
  • GarberA.J. et al.

    Efficacy of metformin in type II diabetes: Results of a double blind, placebo-controlled, closeresponse trial

    Am J Med

    (1997)
  • GrantP.J.

    The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in pa tients with type II diabetes

    Diabetes Care

    (1996)
  • GrantP.J.

    The effects of metformin on cardiovascular risk factors

    Diabetes Metab Rev

    (1995)
  • McIntyreH.D. et al.

    Metformin increases insulin sensitivity and basal glucose clearance in type 2 (non-insulin dependent) diabetes mellitus

    Aust N Z J Med

    (1991)
  • StrattonI. et al.

    Is the cardioprotective effect of metformin in type 2 diabetes dose dependent?

    Diabetes

    (2003)
  • LebovitzH.E. et al.

    Rosiglitazone monotherapy is effective in patients with type 2 diabetes

    J Clin Endocrinol Metab

    (2001)
  • St John SuttonM. et al.

    A comparison of the effects of rosiglitazone and gly buride on cardiovascular function and glycemic control in patients with type 2 diabetes

    Diabetes Care

    (2002)
  • HaffnerS.M. et al.

    Effect of rosiglitazone treatment on nontraditional mark ers of cardiovascular disease in patients with type 2 diabetes mellitus

    Circulation

    (2002)
  • Cited by (67)

    • A Systematic Review of Patient-Reported Satisfaction with Oral Medication Therapy in Patients with Type 2 Diabetes

      2018, Value in Health
      Citation Excerpt :

      Nevertheless, the only instrument designed for patients on oral therapy was the DTSQ. The DTSQs has been shown to be responsive when average initial satisfaction scores are less than 30 [38,41–43], yet when respondents are more satisfied with their current therapy at baseline, the DTSQs is not able to differentiate patient satisfaction, even if patients in the treatment group achieve significantly better glycemic control [44–48]. It is challenging to measure satisfaction with medication in a clinically meaningful way with the limited data currently available.

    • The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact

      2011, Trends in Pharmacological Sciences
      Citation Excerpt :

      Thus, combination therapy with metformin and TZDs could yield additive effects on hepatic and peripheral glucose metabolism. Table 2 summarizes the effects of adding TZD to metformin therapy in T2DM and clearly shows further lowering of FPG and peripheral insulin resistance [98–103]. There is also evidence that combined metfomin–TZD regimens are superior to the effect of adding sulfonylurea drugs to metformin therapy [104,105].

    • Adherence to Oral Antidiabetic Agents with Pioglitazone and Metformin: Comparison of Fixed-Dose Combination Therapy with Monotherapy and Loose-Dose Combination Therapy

      2011, Clinical Therapeutics
      Citation Excerpt :

      Monotherapy (MT) with oral antidiabetic agents (OADs) is the first-line pharmacologic treatment option(s); however, patients with more severe diabetes are managed with dual therapy. 9,10 Glycemic control has been shown to improve not only with dual therapy (compared with MT),11–15 but also with fixed-dose combination therapy (FDCT) (compared with loose-dose combination therapy [LDCT]).16,17 Although use of 2 agents may achieve better glycemic control, studies have shown that medication adherence typically decreases with the addition of another agent.18,19

    • Can the Mediterranean diet lower HbA1c in type 2 diabetes? Results from a randomized cross-over study

      2011, Nutrition, Metabolism and Cardiovascular Diseases
      Citation Excerpt :

      However, this current study is one of the few studies to examine the impact of a traditional Mediterranean-type diet (in a randomized cross-over trial), in its entirety, where the majority of foods (>70%) are provided to subjects, on weight and metabolic control of type 2 diabetes. The intervention resulted in a statistically and clinically significant improvement in glycemic control, equivalent to mono drug therapy [20–22]. Adherence to the prescribed diet was good, as indicated by changes in plasma biomarkers (MUFA, lutein and lycopene).

    View all citing articles on Scopus
    View full text